The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-24. Anything still debated is marked as such rather than presented as settled.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
== Creationism == A Methodist from age ten, and later a fundamentalist Baptist, Gish believed that the Genesis creation narrative was historical fact. After reading the booklet Evolution, "Science Falsely So-called" in the late 1950s, Gish became persuaded that science had produced falsifiable evidence against evolutionary theory, particularly the origin of life, and that various fields of science offered corroborating evidence in support of the Genesis creation narrative. He joined the American Scientific Affiliation (ASA), an association of Christian scientists, mistakenly assuming the group supported creationism. Through his affiliation at the ASA, Gish met geneticist and creationist William J. Tinkle, who in 1961 invited Gish to join a newly formed anti-evolution caucus within the ASA. In 1971, Gish became a member of the faculty at San Diego Christian College, working in its research division before accepting a position at the Institute for Creation Research (independent since 1981). He was the author of several books and articles espousing creationism. His best-known work, Evolution: The Fossils Say No!, published in 1972, has been widely accepted by creationists as an authoritative reference. Gish initially "assigned low priority to the question of [the] age [of the Earth]". At his death on March 5, 2013, Gish held the position of Senior Vice-President Emeritus at the ICR.
Severe sexual dysfunction, including loss of libido, anorgasmia, lack of vaginal lubrication, and erectile dysfunction, is one of the most commonly encountered adverse effects of treatment with paroxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is higher than 70%. Paroxetine has consistently been found to have the highest rate of sexual side effects among the SSRIs. In some patients, these effects persist after discontinuation of the drug, a condition known as post-SSRI sexual dysfunction (PSSD). Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. The DSM-5 noted in 2013 that serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is discontinued. Paroxetine was among the earliest SSRIs to be associated with persistent sexual dysfunction in the peer-reviewed literature. A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction at approximately 0.46% of patients treated with serotonergic antidepressants, including SSRIs, though the actual prevalence remains uncertain and the condition is likely underreported.
=== Absorption === The oral bioavailability of testosterone is very low. The bioavailability of oral testosterone undecanoate is 3 to 7%. Topical testosterone gels have a bioavailability of about 8 to 14% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs. The bioavailability of testosterone by subcutaneous implant is virtually 100%. The bioavailability of drugs that are administered intramuscularly is generally almost 95%.
Sources: en.wikipedia.org
=== As NCCAM (1998–2014) === In 2008 Josephine Briggs was appointed as director of NCCAM. She was "a nephrologist with impeccable scientific credentials". The appointment was considered surprising since she did not have a complementary and alternative medicine background or integrative medicine background. Writing for Science-Based Medicine, David Gorski states Briggs was in an impossible position: "She was a real scientist trying to impose scientific rigor on an enterprise that was inherently resistant to such an imposition." She attempted to impose a more scientific approach with two long-term strategic plans. The plans used "one of the most harmful tactics of quacks to legitimize their quackery under the banner of 'integrative medicine,' the co-opting of the opioid crisis as an excuse to claim all nonpharmacological treatments for pain as being 'integrative.' The results are threatening great harm to chronic pain patients by misguided governments wanting to force them to undergo quack treatments like acupuncture as a means of getting them off opioids." However, she was able to eliminate studies on homeopathy and tried to counter anti-vaccine beliefs. Energy healing was "relegated to the fringes, if not eliminated". Most of the studies became centered around nutrition, exercise, pharmacognosy, "and other modalities within the realm of science-based medicine". In 2009, after 17 years of government testing for $2.5 billion, almost no clearly proven efficacy of alternative therapies had been found.
The AAA proteins contain two domains, an N-terminal alpha/beta domain that binds and hydrolyzes nucleotides (a Rossmann fold) and a C-terminal alpha-helical domain. The N-terminal domain is 200-250 amino acids long and contains Walker A and Walker B motifs, and is shared in common with other P-loop NTPases, the superfamily which includes the AAA family. Most AAA proteins have additional domains that are used for oligomerization, substrate binding and/or regulation. These domains can lie N- or C-terminal to the AAA module. Some classes of AAA proteins have an N-terminal non-ATPase domain which is followed by either one or two AAA domains (D1 and D2). In some proteins with two AAA domains, both are evolutionarily well conserved (like in Cdc48/p97). In others, either the D2 domain (like in Pex1p and Pex6p) or the D1 domain (in Sec18p/NSF) is better conserved in evolution. While the classical AAA family was based on motifs, the family has been expanded using structural information and is now termed the AAA family.
and Canada, calcium is instead produced by reducing lime with aluminium at high temperatures. In this process, powdered high-calcium lime and powdered aluminum are mixed and compacted into briquettes for a high degree of contact, which are then placed in a sealed retort which has been evacuated and heated to ~1200°C. The briquettes release calcium vapor into the vacuum for about 8 hours, which then condenses in the cooled ends of the retorts to form 24-34 kg pieces of calcium metal, as well as some residue of calcium aluminate. High-purity calcium can be obtained by distilling low-purity calcium at high temperatures.
On 18 March, Israel struck the South Pars natural gas field in the Persian Gulf and its neighboring refineries in Iran with US coordination. In retaliation, Iran attacked the world's largest LNG production facility in Qatar, while Trump claimed he had no knowledge of the South Pars attack. Israel said it had killed Iranian intelligence minister Esmaeil Khatib in an overnight airstrike. Pezeshkian confirmed Khatib's killing. A hair salon in Beit Awwa was struck by a projectile, killing four women, with Israeli authorities stating that it was most likely cluster munitions and Palestinian authorities saying it was an errant Israeli interceptor. On 19 March, a US F-35 made an emergency landing after a suspected hit by Iranian forces. A BAZAN Group refinery in Haifa was hit during a broader Iranian missile attack on the area as a retaliation for Israeli attacks on South Pars gas facilities. Netanyahu insisted that "You can't make a revolution from the air" and that "there must be a ground component—I won't share with you all the options", implying that there was a potential for limited assault operations involving soldiers on the ground in Iran. The US began an aerial campaign against Iranian vessels and drones in the Strait of Hormuz in an effort to reopen it to international shipping.
Sources: en.wikipedia.org
This theoretical analysis of the various isomers and experimental analysis of this reaction cast doubt on whether the mass spectrometric approach really did produce the hexathione isomer as originally claimed. The increased stability of dithietes as compared to dioxetane-like rings is one of theoretical bases for proposing C6S6 is more stable than the oxygen analog.
=== Influence of Vladimir Cerrón === Vladimir Cerrón is the General Secretary of Free Peru, who represents the Marxist–Leninist faction of the party. Cerrón was previously the governor of Junín, but was convicted for corruption and given a suspended sentence. Cerrón has repeatedly denied such charges, stating that he's a victim of lawfare and political persecution. The indictment prevents Cerrón from running for public office. During the 2021 Peruvian general election, Castillo distanced himself from Cerrón, saying that Cerrón "will not even be a doorman in any of the institutions of the State." However, Castillo has been accused of appointing government officials and ministers who are close to Cerrón. These include the appointment of Waldemar Cerrón, Vladimir's brother, as Free Peru's spokesman in Congress, despite Waldemar being investigated for money laundering. Waldemar has also been under investigation in Los Dinámicos del Centro, an alleged criminal organization that's investigated for money laundering. The investigations also include Vladimir and then Prime Minister Bellido. Vladimir has accused the investigations of being political persecution. Later, a number of alleged members of Los Dinámicos del Centro escaped from the country. Prime Minister Mirtha Vásquez stated that they have been included in Peru's registry of most wanted fugitives.
== List of people with the surname == Andy Merrifield (born 1960), British Marxist urban theorist Charles T. Merrifield (c. 1924–1957), American uranium miner and murder victim Charles Watkins Merrifield (1827–1884), British mathematician Dave Merrifield (born 1941), Canadian ice hockey player Donald Merrifield (1928–2010), American Jesuit Eric Mowbray Merrifield, South African engineer, inventor of the dolos Flora Merrifield (1859–1943), British suffragist Frankie Merrifield (born 1994), English footballer Frederick Merrifield (1831–1924), English lepidopterist John H. Merrifield (1847–1906), American politician Lane Merrifield, Canadian entrepreneur, co-creator of Club Penguin Leonard Stanford Merrifield (1880–1943), British sculptor Lester Levern Merrifield (1921–2000), American orthodontist Louisa May Merrifield (1906–1953), British poisoner Mary Philadelphia Merrifield (1804–1889), British algologist and writer Michael Merrifield (born 1946/47), American politician Michael Merrifield, English astronomer and professor Ralph Merrifield (1913–1995), English museum curator and archaeologist Renee Merrifield, Canadian politician Rob Merrifield (born 1953), Canadian politician and diplomat Robert Bruce Merrifield (1921–2006), American biochemist, inventor of solid phase peptide synthesis Samuel Merrifield (1904–1982), Australian politician Webster Merrifield (1852–1916), American educator and academic Whit Merrifield (born 1989), American baseball player William Merrifield (1890–1943), Canadian Victoria Cross recipient
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.